The protective effect of DR3 was dependent on ILC2 secretion of IL-5 and IL-13; therefore, the observed secretion of IL-5 and IL-13 in human ILC2s with DR3 engagement in the study shows that DR3 may be a therapeutic target in human T2DM. Here, IL5 is linked to type 2 diabetes mellitus.